Technology
Health
Biotechnology

Insmed

$26.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.51 (1.98%) Today
-$0.33 (-1.25%) After Hours

Why Robinhood?

You can buy or sell Insmed and other stocks, options, ETFs, and crypto commission-free!

About

Insmed, Inc. Common Stock, also called Insmed, is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Read More Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Employees
373
Headquarters
Bridgewater, New Jersey
Founded
1988
Market Cap
2.04B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
933.17K
High Today
$26.46
Low Today
$25.83
Open Price
$25.88
Volume
333.97K
52 Week High
$33.13
52 Week Low
$11.31

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Pharmaceutical
US
North America

News

Seeking AlphaMay 24

Insmed closes $250M capital raise

Insmed (INSM +0.6% ) has closed its public offering of ~9.6M common shares at $26 per share. Gross proceeds were ~$250M. Underwriters have a 30-day option to buy up to an additional ~1M shares from the company and up to 400K shares from Chairman & CEO William Lewis....

12
Seeking AlphaMay 20

Insmed's Arikayce shows sustained benefit in late-stage lung disease study

New data from a Phase 3 clinical trial, CONVERT, evaluating Insmed's (NASDAQ:INSM) ARIKAYCE (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease showed a durable treatment effect when added to guideline-based therapy (GBT) compared to GBT alone.

66
The Motley FoolMay 8

Insmed (INSM) Q1 2019 Earnings Call Transcript

Insmed (NASDAQ:INSM) Q1 2019 Earnings Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Insmed conference call to discuss the company's first-quarter financial results. [Operator instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Blaine Davis, head of investor relations. You may begin. Blaine Davis -- He...

26

Earnings

-$1.19
-$1.01
-$0.82
-$0.64
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.